Oxford Asset Management LLP Buys New Shares in Nevro Corp. (NYSE:NVRO)

Oxford Asset Management LLP bought a new stake in Nevro Corp. (NYSE:NVRO) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 10,577 shares of the medical equipment provider’s stock, valued at approximately $39,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. American Century Companies Inc. boosted its holdings in Nevro by 12.9% in the fourth quarter. American Century Companies Inc. now owns 37,041 shares of the medical equipment provider’s stock valued at $138,000 after purchasing an additional 4,224 shares during the period. SG Americas Securities LLC boosted its holdings in Nevro by 34.6% in the fourth quarter. SG Americas Securities LLC now owns 17,126 shares of the medical equipment provider’s stock valued at $64,000 after purchasing an additional 4,406 shares during the period. Wells Fargo & Company MN lifted its holdings in Nevro by 29.9% during the 4th quarter. Wells Fargo & Company MN now owns 21,595 shares of the medical equipment provider’s stock worth $80,000 after buying an additional 4,971 shares during the last quarter. Virtu Financial LLC lifted its holdings in Nevro by 59.9% during the 4th quarter. Virtu Financial LLC now owns 17,956 shares of the medical equipment provider’s stock worth $67,000 after buying an additional 6,725 shares during the last quarter. Finally, PNC Financial Services Group Inc. lifted its holdings in Nevro by 62.3% during the 4th quarter. PNC Financial Services Group Inc. now owns 20,548 shares of the medical equipment provider’s stock worth $76,000 after buying an additional 7,889 shares during the last quarter. 95.52% of the stock is currently owned by hedge funds and other institutional investors.

Nevro Stock Performance

Shares of NVRO stock opened at $5.85 on Tuesday. The stock has a market capitalization of $224.32 million, a PE ratio of -3.09 and a beta of 0.81. Nevro Corp. has a 52-week low of $3.17 and a 52-week high of $11.79. The stock’s 50-day moving average price is $5.81 and its 200 day moving average price is $5.05. The company has a quick ratio of 3.76, a current ratio of 5.02 and a debt-to-equity ratio of 0.67.

Nevro (NYSE:NVRO) last issued its quarterly earnings results on Tuesday, March 4th. The medical equipment provider reported ($0.64) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.79) by $0.15. The firm had revenue of $105.55 million for the quarter, compared to analysts’ expectations of $102.61 million. Nevro had a negative return on equity of 23.52% and a negative net margin of 16.54%. As a group, equities research analysts forecast that Nevro Corp. will post -2.44 EPS for the current year.

Analyst Ratings Changes

A number of analysts have issued reports on NVRO shares. Canaccord Genuity Group lifted their price target on Nevro from $4.00 to $5.85 and gave the stock a “hold” rating in a report on Friday, February 7th. Piper Sandler raised Nevro from a “neutral” rating to an “overweight” rating and decreased their price target for the stock from $6.00 to $5.85 in a report on Friday, February 7th. Jefferies Financial Group raised Nevro from an “underperform” rating to a “hold” rating and lifted their price target for the stock from $4.50 to $5.85 in a report on Monday, February 10th. Finally, StockNews.com started coverage on Nevro in a report on Wednesday, April 23rd. They set a “hold” rating for the company. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat.com, Nevro has an average rating of “Hold” and a consensus price target of $5.36.

Nevro Company Profile

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems.